Abstract
Background
The prevalence of Alzheimer's disease is steadily increasing, and Aducanumab has garnered significant attention as a treatment since 2021. There is a growing body of research on Aducanumab and its relationship with Alzheimer's disease; however, there is currently a lack of bibliometric analysis regarding the use of Aducanumab in the treatment of Alzheimer's disease.
Objective
This study employs bibliometric methods to analyze the current research landscape and hotspots surrounding Alzheimer's disease and Aducanumab, providing a reference for subsequent investigations in this field and the promotion of Aducanumab as a treatment for Alzheimer's disease.
Methods
This study retrieved articles related to Alzheimer's disease and Aducanumab from the WOS core database, covering the period from the establishment of the database until Dec 31, 2024. After a rigorous selection process, analyses were conducted using GraphPad Prism 10, VOSviewer, and CiteSpace to obtain insights into publication and citation metrics, collaboration networks among countries, institutions, and authors, as well as clustering analysis of reference papers and keywords.
Results
The number of articles regarding Aducanumab treatment for Alzheimer's disease has been increasing annually, with a notable surge occurring after 2021. The three countries with the highest publication output are the United States, the United Kingdom, and China. The leading institutions in terms of publication volume are Biogen, Harvard Medical School, and the University of California, San Francisco. The top three authors contributing to this body of work are Poul F. Høilund-Carlsen, Abass Alavi, and Mona-Elisabeth Revheim. The journals with the highest publication rates include Alzheimer's & Dementia, the International Journal of Molecular Sciences, and the Journal of Alzheimer's Disease. The most cited article is "Lecanemab in Early Alzheimer's Disease," authored by van Dyck CH et al., published in 2023 in the New England Journal of Medicine. The ten most frequently occurring keywords are Alzheimer's disease, Aducanumab, dementia, amyloid-beta, immunotherapy, tau, a-beta, mouse model, amyloid, and mild cognitive impairment. The keyword and cluster "pharmacokinetics" currently represent a research hotspot in this field.
Conclusion
This study employs bibliometric methods to reveal the publication trends related to Aducanumab in the context of Alzheimer’s disease, examining collaborations among countries, regions, and authors, as well as recent research hotspots. It provides objective data that serves as a reference for scientific research and clinical practice concerning Aducanumab treatment for Alzheimer’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All primary data utilized in this research can be accessed upon a justified request.
References
Amrapala A, Sabé M, Solmi M, Maes M (2023) Neuropsychiatric disturbances in mild cognitive impairment: A scientometric analysis. Ageing Res Rev 92:102129. https://doi.org/10.1016/j.arr.2023.102129
Ashvin DR, Kumari S, Sharma P, Vellingiri B, Medhi B et al. (2025) Unraveling the immune puzzle: Role of immunomodulation in Alzheimer's disease. J Neuroimmune Pharmacol 20(1):47. https://doi.org/10.1007/s11481-025-10210-9
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al. (2022) Two randomized phase 3 studies of Aducanumab in early Alzheimer's Disease. J Prev Alzheimers Dis 9(2):197–210. https://doi.org/10.14283/jpad.2022.30
Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT et al. (2024) Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med 221(2). https://doi.org/10.1084/jem.20231363
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M (2021) Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis 8(4): 398–410. https://doi.org/10.14283/jpad.2021.41
Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S et al. (2022) Aducanumab: Appropriate use recommendations update. J Prev Alzheimers Dis 9(2): 221–230. https://doi.org/10.14283/jpad.2022.34
Dhillon S (2021) Aducanumab: First approval. Drugs 81(12):1437–1443. https://doi.org/10.1007/s40265-021-01569-z
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S et al (2021) Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol 20(6):484–496. https://doi.org/10.1016/s1474-4422(21)00066-1
Dunn B, Stein P, Cavazzoni P (2021) Approval of Aducanumab for Alzheimer Disease-The FDA’s perspective. JAMA Intern Med 181(10):1276–1278. https://doi.org/10.1001/jamainternmed.2021.4607
Fillit H, Green A (2021) Aducanumab and the FDA - where are we now? Nat Rev Neurol 17(3):129–130. https://doi.org/10.1038/s41582-020-00454-9
Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K et al (2018) Japanese and North American Alzheimer’s Disease neuroimaging initiative studies: Harmonization for international trials. Alzheimers Dement 14(8):1077–1087. https://doi.org/10.1016/j.jalz.2018.03.009
Jucker M, Walker LC (2023) Alzheimer’s disease: From immunotherapy to immunoprevention. Cell 186(20):4260–4270. https://doi.org/10.1016/j.cell.2023.08.021
Kandadi Muralidharan K, Tong X, Kowalski KG, Rajagovindan R, Lin L, Budd Haberlain S et al (2022) Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer’s disease. CPT Pharmacometrics Syst Pharmacol 11(1):7–19. https://doi.org/10.1002/psp4.12728
Khan S, Barve KH, Kumar MS (2020) Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s Disease. Curr Neuropharmacol 18(11):1106–1125. https://doi.org/10.2174/1570159x18666200528142429
Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O’Gorman J et al (2024) Genome-wide association studies of ARIA from the Aducanumab phase 3 ENGAGE and emerge studies. Neurology 102(3):e207919. https://doi.org/10.1212/wnl.0000000000207919
Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I et al. (2021) Donanemab (LY3002813) phase 1b study in Alzheimer's disease: Rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis 8(4): 414–424. https://doi.org/10.14283/jpad.2021.56
Lozupone M, Dibello V, Resta E, Sardone R, Castellana F, Zupo R et al. (2025) Uncertainties in Anti-Amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead. Expert Rev Neurotherhttps://doi.org/10.1080/14737175.2025.2500752
Maheshwari S, Singh A, Ansari VA, Mahmood T, Wasim R, Akhtar J et al (2024) Navigating the dementia landscape: Biomarkers and emerging therapies. Ageing Res Rev 94:102193. https://doi.org/10.1016/j.arr.2024.102193
Menegaz de Almeida A, Leite M, Lopes LM, Gomes Lima P, Siegloch Barros ML, Rocha Pinheiro S et al (2024) Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis. Expert Rev Neurother 24(9):929–936. https://doi.org/10.1080/14737175.2024.2367016
Millet A, Ledo JH, Tavazoie SF (2024) An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains. Immunity 57(1):153-170.e156. https://doi.org/10.1016/j.immuni.2023.12.001
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW et al (2021) Donanemab in early Alzheimer’s disease. N Engl J Med 384(18):1691–1704. https://doi.org/10.1056/NEJMoa2100708
Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I et al (2025) Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer’s disease. Expert Opin Biol Ther 25(3):275–283. https://doi.org/10.1080/14712598.2025.2463963
Rabinovici GD (2021) Controversy and progress in Alzheimer’s disease - FDA approval of Aducanumab. N Engl J Med 385(9):771–774. https://doi.org/10.1056/NEJMp2111320
Restifo LL, Erickson RP (2023) Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer's disease: A case report. SAGE Open Med Case Rep 11, 2050313x231194507. https://doi.org/10.1177/2050313x231194507
Reynolds KS (2013) Acceleration of drug development: a collaboration of many stakeholders. Clin Pharmacol Ther 93(6):455–459. https://doi.org/10.1038/clpt.2013.63
Rezai AR, D’Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K et al (2024) Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer’s disease. N Engl J Med 390(1):55–62. https://doi.org/10.1056/NEJMoa2308719
Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A et al (2024) Alzheimer’s disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med (Lausanne) 11:1474043. https://doi.org/10.3389/fmed.2024.1474043
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease. JAMA Neurol 79(1):13–21. https://doi.org/10.1001/jamaneurol.2021.4161
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333. https://doi.org/10.1056/NEJMoa1304839
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE et al (2021) Alzheimer’s disease. Lancet 397(10284):1577–1590. https://doi.org/10.1016/s0140-6736(20)32205-4
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537(7618):50–56. https://doi.org/10.1038/nature19323
Tanne JH (2023) Aduhelm: Approval of Alzheimer’s drug was highly unorthodox, finds report. BMJ 380:6. https://doi.org/10.1136/bmj.p6
Tatulian SA (2022) Challenges and hopes for Alzheimer’s disease. Drug Discov Today 27(4):1027–1043. https://doi.org/10.1016/j.drudis.2022.01.016
Terao I, Kodama W (2024) Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer’s disease: A systematic review and network meta-analysis. Ageing Res Rev 94:102203. https://doi.org/10.1016/j.arr.2024.102203
Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M et al. (2024) Japanese subgroup analyses from EMERGE and ENGAGE, phase 3 clinical trials of Aducanumab in patients with early Alzheimer's disease. J Prev Alzheimers Dis 11(5):1260–1269. https://doi.org/10.14283/jpad.2024.106
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in Early Alzheimer’s disease. N Engl J Med 388(1):9–21. https://doi.org/10.1056/NEJMoa2212948
Walsh S, Merrick R, Milne R, Brayne C (2021) Aducanumab for Alzheimer’s disease? BMJ 374:n1682. https://doi.org/10.1136/bmj.n1682
Woodcock J, Woosley R (2008) The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1–12. https://doi.org/10.1146/annurev.med.59.090506.155819
Funding
This study was supported by the Shanxi Provincial University of Higher Science and Technology Innovation Plan (Grant No. 2021L252), the Shanxi Province Basic Research Plan (Grant No. 202303021222355), the "Qing Lan Project" of Jiangsu Province, and Yangzhou Polytechnic College.
Author information
Authors and Affiliations
Contributions
Zhe Yang designed the study. Dingwen Xu, Jijun Wu and Jiaxing Shen performed analysis used VOSviewer and wrote the draft. Xu Zhao and Zhihua Lu conducted analysis used Citespace. The authors declare that all data were generated in-house and that no paper mill was used.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Patient consent statement
Not applicable.
Clinical trial number
Not applicable.
AI used
The authors confirm that no paper mill and no artificial intelligence was used.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xu, D., Wu, J., Zhao, X. et al. A bibliometric analysis of the current research status and hotspots regarding Aducanumab treatment for Alzheimer's disease. Naunyn-Schmiedeberg's Arch Pharmacol 399, 531–547 (2026). https://doi.org/10.1007/s00210-025-04448-6
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1007/s00210-025-04448-6